Prospective Double-Blind PBO-Controlled Combined Crossover Randomized Withdrawal Study of Latiglutenase in T1D/CD Pts
Condition:   Celiac Disease Interventions:   Drug: Latiglutenase;   Drug: Placebo Sponsors:   Immunogenics, LLC;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2021 Category: Research Source Type: clinical trials